|Bid||34.77 x 400|
|Ask||34.78 x 2400|
|Day's Range||34.60 - 34.90|
|52 Week Range||25.55 - 35.60|
|PE Ratio (TTM)||26.03|
|Dividend & Yield||1.90 (5.42%)|
|1y Target Est||N/A|
AstraZeneca PLC (AZN) announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Faslodex for 1st-line treatment for postmenopausal women with HR+ advanced breast cancer.
The agenda was dominated by eurozone economic data, the anniversary of Britain's vote to leave the EU and a political summit in Brussels on Friday.
Tesaro's Zejula would likely outperform drugs from Clovis and AstraZeneca in immuno-oncology combinations with Merck, Bristol or Roche.